Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Gynecologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma, Follicular 2Carcinoma, Renal Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 72apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × utomilumab × Clear all
NCT02554812 2024-07-30

JAVELIN Medley

Pfizer

Phase 1/2 Terminated
409 enrolled 108 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02315066 2022-04-21

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Pfizer

Phase 1 Completed
174 enrolled 68 charts
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡